Health Condition 1: null- Iron Deficiency Anaemia
Conditions
Interventions
Intervention1: Mandura Vataka: Dose: 500 mg (two tablets of 250 mg) twice daily / 1gm per day Dosage form: Tablet
Route of Administration:Oral
Time of Administration : Twice a day before food
Duration
Sponsors
CCRAS New Delhi
Eligibility
Inclusion criteria
Inclusion criteria: 1.Patients of either sex aged between 18 to 50 years. 2.Patients with iron deficiency anaemia (Hb 6gm-10gm), 3.S. Ferritin 4.S.Iron content 5.MCHC 6.MCV 7.Peripheral smear picture suggestive of Microcytic Hypochromic Anaemia 8.Willing and able to participate for 84 days
Exclusion criteria
Exclusion criteria: 1.Stool examination found with positive ova/cyst/parasite of worm infestation 2.Any continuing blood loss due to haematemesis, melena and bleeding piles etc 3.Dimorphic anaemia 4.Patients who cannot report in person every 2 weeks in the OPD 5.Patients with poorly controlled Hypertension ( >160/100 mmHg) 6.Patients with poorly controlled Diabetes Mellitus having Hb A1C of > 7.5% 7.Patients with evidence of malignancy 8.History of chronic infections. 9.Patients on medication with any other drugs that may have an influence on the outcome of the study. 10.Known case of cardiovascular diseases 11.Known HIV positive cases 12.Patients with concurrent serious hepatic disorder (defined as Aspartate Amino Transferase (AST) and / or Alanine Amino Transferase (ALT), Total Bilirubin, Alkaline Phosphatase (ALP) > 2 times upper normal limit), Severe Pulmonary Dysfunction (uncontrolled Bronchial Asthma and / or Chronic Obstructive Pulmonary Disease [COPD]), 13.Alcoholics and/or drug abusers 14.H/o hypersensitivity to any of the trial drugs or their ingredients 15.Pregnant/lactating woman. 16.Patients who have completed participation in any other clinical trial during the past six months. 17.Any other condition which the Investigator thinks may jeopardize the study.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Symptomatic relief,Change (increase) in Serrum Ferritin level and normacy of Peripheral Blood Smear picture Timepoint: 28th, 56th, and 84th day | — |
Primary
| Measure | Time frame |
|---|---|
| Change (increase) in Hb%Timepoint: Change (increase) in Hb% | — |
Countries
India
Contacts
Public ContactDr Babita Yadav
Central council for Research in Ayurvedic Sciences, New Delhi
Outcome results
None listed